<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11735">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02088606</url>
  </required_header>
  <id_info>
    <org_study_id>VP-002 527 Version H</org_study_id>
    <nct_id>NCT02088606</nct_id>
  </id_info>
  <brief_title>TactiCath® Contact Force Ablation Catheter Study for Atrial Fibrillation Continued Access Protocol</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective,  multicenter, interventional study to collect confirmatory evidence on the
      safety and effectiveness of the TactiCath® percutaneous ablation catheter for the treatment
      of symptomatic paroxysmal atrial fibrillation using contact force assisted irrigated
      radiofrequency ablation.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Electrical isolation of all 4 PVs, or in the event of a common PV, the clinical equivalent of all PVs, by the end of index procedure</measure>
    <time_frame>30 min post ablation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Acute procedural success and freedom from recurrence of symptomatic AF, AFL, and AT lasting longer than 30 seconds through 9 months of follow-up after a 3 month blanking period. Re-treatment for AF with ablation after 3 months is a failure</measure>
    <time_frame>12 months post ablation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Device-related early onset primary SAEs occurring within 7 days of the index procedure</measure>
    <time_frame>7 days post ablation</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Paroxysmal Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>TactiCath Quartz</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TactiCath Quartz treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TactiCath Quartz treatment</intervention_name>
    <description>Catheter ablation for the treatment of paroxysmal atrial fibrillation</description>
    <arm_group_label>TactiCath Quartz</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  symptomatic PAF (Paroxysmal Atrial Fibrillation)refractory to at least one Class I-IV
             antiarrhythmic drug

          -  minimum one documented PAF episode &gt;30 sec duration within prior 12 months

          -  minimum three PAF episodes during prior 12 months

          -  18 years or older

        Exclusion Criteria:

          -  persistent or long-standing persistent AF(Atrial Fibrillation)

          -  four or more cardioversions in prior 12 months

          -  MI (myocardial infarction), CABG (coronary artery bypass graft) or PCI (percutaneous
             coronary intervention) within preceding 3 months

          -  left atrial diameter &gt; 5.0 cm

          -  LVEF (left ventricular ejection fraction)&lt; 35%

          -  NYHA (New York Heart Association) class III or IV

          -  previous left atrial ablation procedure

          -  previous tricuspid or mitral valve repair surgery
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicole Glowacki</last_name>
    <phone>6517563432</phone>
    <email>nglowacki@sjm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabina Sayeed</last_name>
      <email>ssayeed@partners.org</email>
    </contact>
    <investigator>
      <last_name>Moussa Mansour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 13, 2014</lastchanged_date>
  <firstreceived_date>March 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
